Mersana Therapeutics (MRSN) Receiving Somewhat Favorable Press Coverage, Report Shows
Media coverage about Mersana Therapeutics (NASDAQ:MRSN) has trended somewhat positive recently, Accern Sentiment reports. Accern identifies positive and negative media coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Mersana Therapeutics earned a news sentiment score of 0.02 on Accern’s scale. Accern also assigned media coverage about the company an impact score of 45.2768090722107 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
Mersana Therapeutics (NASDAQ MRSN) opened at $14.76 on Wednesday. The company has a market cap of $335.84 and a P/E ratio of -14.33. Mersana Therapeutics has a 12 month low of $12.45 and a 12 month high of $21.01.
Several equities analysts have recently weighed in on MRSN shares. HC Wainwright set a $33.00 target price on shares of Mersana Therapeutics and gave the stock a “buy” rating in a research note on Friday, March 2nd. Zacks Investment Research upgraded shares of Mersana Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, January 11th. Finally, ValuEngine upgraded shares of Mersana Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Friday, February 2nd. One analyst has rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the stock. Mersana Therapeutics has an average rating of “Buy” and an average target price of $26.00.
COPYRIGHT VIOLATION WARNING: “Mersana Therapeutics (MRSN) Receiving Somewhat Favorable Press Coverage, Report Shows” was first posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this article on another site, it was copied illegally and reposted in violation of United States & international trademark and copyright law. The correct version of this article can be read at https://www.thecerbatgem.com/2018/03/14/mersana-therapeutics-mrsn-receiving-somewhat-favorable-press-coverage-report-shows.html.
Mersana Therapeutics, Inc is a United States-based biotechnology company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs). The Company focuses on advancing a pipeline of targeted oncology therapeutics leveraging its Fleximer immunoconjugate technology. The Fleximer platform allows it to design ADCs with specific properties and manage the drug’s chances of attacking cancers.
Receive News & Ratings for Mersana Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mersana Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.